Cargando…

Diffuse Long Coronary Artery Disease is Still an Obstacle for Percutaneous Coronary Intervention in the Second-Generation Drug-Eluting Stent Era?

Detalles Bibliográficos
Autores principales:	Oh, Pyung Chun, Han, Seung Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675689/ https://www.ncbi.nlm.nih.gov/pubmed/31347314 http://dx.doi.org/10.4070/kcj.2019.0150

Ejemplares similares

Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation
por: Hong, Sung-Jin, et al.
Publicado: (2019)

Gender differences of in-hospital outcomes in patients undergoing percutaneous coronary intervention in the drug-eluting stent era
por: Kim, Hack-Lyoung, et al.
Publicado: (2019)

Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with second-generation drug-eluting stents for patients with multivessel and unprotected left main coronary artery disease
por: Papadopoulos, Kyriacos, et al.
Publicado: (2017)

Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost–benefit analysis
por: Poder, Thomas G., et al.
Publicado: (2017)

Impact of Chronic Kidney Disease on Clinical Outcomes in Diabetic Patients Undergoing Percutaneous Coronary Intervention in the Era of Newer-Generation Drug-Eluting Stents
por: Kim, Su-Min, et al.
Publicado: (2017)

Newer-Generation Drug-Eluting Stents in Patients Undergoing Complex Percutaneous Coronary Intervention
por: Otsuka, Kenichiro
Publicado: (2021)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Clinical Implications of Early Exercise Treadmill Testing after Percutaneous Coronary Intervention in the Drug-eluting Stent Era
por: Cho, Sung Woo, et al.
Publicado: (2020)

Prognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stents
por: Kubo, Motoki, et al.
Publicado: (2015)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Coronary artery perforation successfully treated with a second drug-eluting stent
por: Strycek, Matej, et al.
Publicado: (2023)

Five-year major clinical outcomes between first-generation and second-generation drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention
por: Kim, Yong Hoon, et al.
Publicado: (2018)

Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2017)

The Impact of Renal Dysfunction on the Long Term Clinical Outcomes of Diabetic Patients Undergoing Percutaneous Coronary Intervention in the Drug-Eluting Stent Era
por: Choi, Ki Hong, et al.
Publicado: (2016)

Safety and Efficacy of Post-Dilation in Percutaneous Coronary Intervention Using Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents
por: Shin, Yonghoon, et al.
Publicado: (2023)

Stent underexpansion in angiographic guided percutaneous coronary intervention, despite adjunctive balloon post-dilatation, in drug eluting stent era
por: Taherioun, Mehrdad, et al.
Publicado: (2014)

Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome
por: Jang, Ji-Yong, et al.
Publicado: (2018)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Five-year outcomes of biodegradable versus second-generation durable polymer drug-eluting stents used in complex percutaneous coronary intervention
por: Xu, Na, et al.
Publicado: (2023)

Extended Outcomes of Complex Coronary Disease in the Drug Eluting Stent Era
por: Desrosiers, Kevin P., et al.
Publicado: (2011)

Stent Optimization Using Adjunctive Balloon Dilatation in the Era of Second-Generation Drug-Eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2017)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Coronary pseudoaneurysm 1 week after complex percutaneous coronary intervention with drug‐eluting stent
por: Namazi, Mohammad Hasan, et al.
Publicado: (2020)

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016)

First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study
por: Jeger, Raban, et al.
Publicado: (2016)

A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study
por: Kim, Ung, et al.
Publicado: (2013)

Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents
por: Bibi, Salma, et al.
Publicado: (2022)

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
por: Alazzoni, Ashraf, et al.
Publicado: (2012)

First- Versus Second-Generation Drug-Eluting Stents in Acute Coronary Syndromes (Katowice-Zabrze Registry)
por: Kawecki, Damian, et al.
Publicado: (2016)

Effectiveness and Safety of Zotarolimus-Eluting Stent (Resolute™ Integrity) in Patients with Diffuse Long Coronary Artery Disease
por: Park, Keun-Ho, et al.
Publicado: (2019)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent
por: Kim, Ju-Youn, et al.
Publicado: (2015)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
por: Panoulas, Vasileios F, et al.
Publicado: (2015)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
por: Xiu, Wen-Juan, et al.
Publicado: (2018)

Percutaneous treatment of spontaneous left main coronary artery dissection using drug-eluting stent
por: Graidis, Christos, et al.
Publicado: (2014)

Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses
por: Lee, Jong-Hyeog, et al.
Publicado: (2013)

Second Generation Drug-Eluting Stent Implantation versus Coronary Artery Bypass Grafting in the Treatment of Young Patients with Left Main and/or Multivessel Coronary Disease
por: Chen, Xue, et al.
Publicado: (2020)

Predictive Ability of the SYNergy Between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery Score II for Long-term Mortality in Patients with Three-vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Treated with Second-generation Drug-eluting Stents
por: He, Ji-Qiang, et al.
Publicado: (2015)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hs3ov4jui4kr0iupjl6qacsuo7